Fortunately, evolving evidence obtained from large database analyses of CRC tumors have identified DDR-based signatures, which may underpin for the eligibility of treatment with novel (e.g., inhibitors of ATR, CHK1, WEE1, and ATM), and marketed DNA repair inhibitors (e.g., PARP inhibitors), and immunotherapy [56]. The gene discussed is PARP1; the disease is colorectal carcinoma.